Pharming Group (NASDAQ:PHAR - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $37.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 320.45% from the company's current price.
Separately, Jefferies Financial Group assumed coverage on Pharming Group in a research note on Monday, December 9th. They set a "buy" rating and a $14.00 target price on the stock.
Read Our Latest Analysis on PHAR
Pharming Group Price Performance
PHAR remained flat at $8.80 during trading on Friday. The company had a trading volume of 6,598 shares, compared to its average volume of 6,221. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The business's 50 day moving average is $8.97 and its 200 day moving average is $8.59. The company has a market capitalization of $598.67 million, a PE ratio of -33.85 and a beta of -0.10. Pharming Group has a 12 month low of $6.65 and a 12 month high of $11.80.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). The firm had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts expect that Pharming Group will post -0.2 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
